Resource Summary Report

Generated by dkNET on Sep 2, 2026

OE19

RRID:CVCL_1622
Type: Cell Line

Proper Citation

RRID:CVCL_1622

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1622

Proper Citation: RRID:CVCL_1622

Description: Cell line OE19 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Esophageal adenocarcinoma

Defining Citation: PMID:9010035, PMID:15511476, PMID:16364037, PMID:20075370, PMID:20164919, PMID:20215515, PMID:22460905, PMID:23795680, PMID:24083764, PMID:25070024, PMID:25877200, PMID:26512696, PMID:26589293, PMID:27397505, PMID:28196595, PMID:30894373, PMID:31068700, PMID:31395879, PMID:34466148, PMID:35839778

Comments: Characteristics: Contains a 100 fold amplification of ERBB2 (PubMed=15511476)., Part of: TCGA-110-CL cell line panel., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: OE19

Synonyms: OE-19, JROECL 19, JROECL19, OEC19

Cross References: CLO:CLO_0008238, EFO:EFO_0002308, CLDB:cl3761, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioSample:SAMN03471032, BioSample:SAMN10988362, cancercelllines:CVCL_1622, Cell_Model_Passport:SIDM00479, ChEMBL-

Cells:CHEMBL3308462, ChEMBL-Targets:CHEMBL1075555, Cosmic:871232, Cosmic:910079, Cosmic:978854, Cosmic:997860, Cosmic:1175878, Cosmic:1599342, Cosmic:1618819, Cosmic:1995600, Cosmic-CLP:910079, DepMap:ACH-000679, DSMZ:ACC-700, DSMZCellDive:ACC-700, ECACC:96071721, EGA:EGAS00001000978, GDSC:910079, GEO:GSM827301, GEO:GSM887475, GEO:GSM888555, GEO:GSM1264050, GEO:GSM1264051, GEO:GSM1264052, GEO:GSM1264053, GEO:GSM1264054, GEO:GSM1264092, GEO:GSM1264093, GEO:GSM1264094, GEO:GSM1264095, GEO:GSM1264096, GEO:GSM1670302, GEO:GSM7701391, GEO:GSM7701392, IARC_TP53:21600, IGRhCellID:OE19, LiGeA:CCLE_923, LINCS_LDP:LCL-1796, PharmacoDB:OE19_1194_2019, PRIDE:PXD030304, Progenetix:CVCL_1622, PubChem_Cell_line:CVCL_1622, Wikidata:Q54931862

ID: CVCL_1622

Record Creation Time: 20220427T221356+0000

Record Last Update: 20260829T235507+0000

Ratings and Alerts

No rating or validation information has been found for OE19.

No alerts have been found for OE19.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 124 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Kang M, et al. (2026) Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells. Molecular cancer therapeutics, 25(5), 814.

Mersich I, et al. (2026) Multi-omic integration identifies broad drug resistance mechanisms and strategies to therapeutically reprogram cancer cells. iScience, 29(1), 114293.

Lobb RJ, et al. (2026) Early-stage multi-cancer detection through a plasma extracellular vesicle protein signature. Cell reports. Medicine, 7(4), 102694.

Krygier K, et al. (2026) A covalent peptide engager approach to equip immunotherapeutic monoclonal and pan IgG serum antibodies with new tumour-targeting function. British journal of pharmacology.

Gaspar M, et al. (2025) An affinity-modulated T cell engager targeting Claudin 18.2 shows potent anti-tumor activity with limited cytokine release. Journal for immunotherapy of cancer, 13(8).

Loong J, et al. (2025) Retroelement co-option disrupts the cancer transcriptional programme. Genome medicine, 17(1), 48.

Plowman T, et al. (2025) Primate retroelement exonization and sexually dimorphic IL13RA1 transcription tune type 2 immune responses. Science immunology, 10(109), eadr1105.

Stamati I, et al. (2025) Anti-HER2, High-DAR Antibody Fragment-Drug Conjugates with a Glucuronide-Based MMAE Linker-Payload Demonstrate Superior Efficacy over IgG-Based ADCs. Molecular cancer therapeutics, 24(9), 1295.

Hosking MP, et al. (2025) Preferential tumor targeting of HER2 by iPSC-derived CAR T cells engineered to overcome multiple barriers to solid tumor efficacy. Cell stem cell, 32(7), 1087.

Yang BH, et al. (2025) iPSC-derived trimodal T cells engineered with CAR, TCR, and hnCD16 modalities can overcome antigen escape in heterogeneous tumors. Cell reports. Medicine, 6(7), 102195.

García-Castillo J, et al. (2025) MicroRNA 196a contributes to the aggressiveness of esophageal adenocarcinoma through the MYC/TERT/NF?B axis. Molecular oncology, 19(11), 3305.

van der Zalm AP, et al. (2024) The pluripotency factor NANOG contributes to mesenchymal plasticity and is predictive for outcome in esophageal adenocarcinoma. Communications medicine, 4(1), 89.

Bozzarelli I, et al. (2024) miRNA-221 and miRNA-483-3p Dysregulation in Esophageal Adenocarcinoma. Cancers, 16(3).

Ballout F, et al. (2024) Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(10), 2193.

Liu D, et al. (2024) Predictive biomarkers for response to TGF- ? inhibition in resensitizing chemo(radiated) esophageal adenocarcinoma. Pharmacological research, 207, 107315.

Amissah OB, et al. (2024) NY-ESO-1-specific T cell receptor-engineered T cells and Tranilast, a TRPV2 antagonist bivalent treatment enhances the killing of esophageal cancer: a dual-targeted cancer therapeutic route. Cancer cell international, 24(1), 64.

Zhong C, et al. (2023) Refined expression quantitative trait locus analysis on adenocarcinoma at the gastroesophageal junction reveals susceptibility and prognostic markers. Frontiers in genetics, 14, 1180500.

Castagnoli L, et al. (2023) Fatty acid synthase as a new therapeutic target for HER2-positive gastric cancer. Cellular oncology (Dordrecht), 46(3), 661.

Li S, et al. (2023) Issues with RNF43 antibodies to reliably detect intracellular location. PloS one, 18(4), e0283894.

Diluvio G, et al. (2023) A novel chemical attack on Notch-mediated transcription by targeting the NACK ATPase. Molecular therapy oncolytics, 28, 307.